Leah Lawrence

Patients with relapsed or refractory CLL had significant delays in progression and death when idelalisib was added to bendamustine and rituximab.

Patients with relapsed/refractory multiple myeloma continue to have deep and durable responses to daratumumab plus lenalidomide/dexamethasone.

The oral BCL-2 inhibitor venetoclax elicited a high rate of response from patients with high-risk relapsed or refractory chronic lymphocytic leukemia with 17p deletion.

Breast cancer survivors with therapy-related leukemia were found to have personal and family histories that suggested an inherited risk for cancer.

Researchers have identified a genetic variant, 2R thymidylate synthase polymorphism, that is associated with an increased risk for avascular necrosis in children with ALL.

A new study has confirmed that the symptom burden of patients with polycythemia vera is substantial, and is independent of a patient’s disease features.

Women older than 70 received less treatment for ovarian cancer than did their younger counterparts, according to the results of a single-center French study.

Chemotherapy plus lenalidomide was shown to be inferior to high-dose melphalan and ASCT in transplant-eligible patients with newly diagnosed multiple myeloma.

Adding elotuzumab to lenalidomide and dexamethasone for the treatment of relapsed or refractory multiple myeloma appears to result in better efficacy and safety.

Women with chemotherapy-naive advanced ovarian cancer gained significant delays in the progression of their disease when adding nintedanib to carboplatin/paclitaxel.

Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.

The FDA approved the proteasome inhibitor ixazomib, in combination with lenalidomide and dexamethasone, to be used as a second-line treatment in multiple myeloma.

PEG-asparaginase had both similar safety and efficacy to intramuscular native E coli l-asparaginase for the treatment of children with ALL in complete remission.

An increased risk for coronary heart disease was found with increasing mean heart dose of radiation in survivors of Hodgkin lymphoma.

Reaching out to underserved populations about colorectal cancer screening using mailed invitations resulted in significantly improved colorectal cancer screening rates in a recently published study.

The use of afatinib failed to show a benefit in HER2-positive breast cancer patients with progressive brain metastases.

Adding the EGFR-targeting drug panitumumab to chemotherapy had no effect on survival in a group of patients with wild-type KRAS status advanced biliary tract cancer.

Results from the phase II SORAML trial indicated that adding sorafenib to standard chemotherapy for younger patients with acute myeloid leukemia was effective, but also resulted in increased toxicity.

The FDA has approved the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF-mutated melanoma.

The use of reduced-intensity conditioning HSCT as a method to maintain remission was effective in a select group of older patients with acute myeloid leukemia.

Researchers testing the use of intermittent high-dose interferon alfa-2b cannot currently recommend the regimen as an adjuvant treatment for high-risk melanoma.

The risk for end-stage renal disease that required renal replacement therapy due to multiple myeloma appears to have declined significantly between 2001 and 2010.

A study in Great Britain found that women diagnosed with female factor infertility were at an increased risk for ovarian cancer.

The FDA has approved its first oncolytic virus therapy talimogene laherparepvec (Imlygic), a drug for the treatment of patients with melanoma lesions in the skin and lymph nodes.

In Hodgkin lymphoma survivors, both mean heart radiation dose and cumulative dose of anthracyclines significantly predicted cardiovascular disease.

Patients with renal cell carcinoma whose disease progressed after previous VEGF therapy saw increased delays in disease progression when treated with lenvatinib.

Muscle attenuation assessed with preoperative CT was an independent prognostic marker in patients with epithelial ovarian cancer.

Patients with metastatic colorectal cancer and a low BMI were at higher risk for disease progression and death; this risk did not affect those with a high BMI.

A new study has found that the number of moles present on one arm could be a useful tool in assessing a person’s risk for melanoma in the primary care setting.

The combination of chemotherapy with the TKI ponatinib was an effective treatment for patients with newly diagnosed Ph-positive acute lymphoblastic leukemia.